Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Piccart

Showing results (101-110 of 186) with videos related to

Pageof 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1994
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials GroupG Catimel, J B Vermorken, M Clavel, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2006
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863)L Beex, C Rose, H Mouridsen, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patientsN Colombo, J L Speyer, M Green, et al.
Investigational New Drugs|November 20, 2012
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumorsA H Awada, H Dumez, A Hendlisz, et al.
Future Oncology (London, England)|September 1, 2021
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancerAditya Bardia, Sara A Hurvitz, Hope S Rugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2013
HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumabL Zabaglo, O Stoss, J Rüschoff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1994
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials GroupJ Verweij, J Wanders, A L Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Successful re-treatment with taxol after major hypersensitivity reactionsD M Peereboom, R C Donehower, E A Eisenhauer, et al.
Breast (Edinburgh, Scotland)|January 26, 2013
Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodesM Saghatchian, S Mook, G Pruneri, et al.
Critical Reviews in Oncology/Hematology|March 4, 2008
A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristicsV Durbecq, L Ameye, I Veys, et al.
Pageof 19

Showing results (101-110 of 186) with videos related to

Sort By:
Pageof 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1994
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials GroupG Catimel, J B Vermorken, M Clavel, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2006
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863)L Beex, C Rose, H Mouridsen, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patientsN Colombo, J L Speyer, M Green, et al.
Investigational New Drugs|November 20, 2012
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumorsA H Awada, H Dumez, A Hendlisz, et al.
Future Oncology (London, England)|September 1, 2021
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancerAditya Bardia, Sara A Hurvitz, Hope S Rugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2013
HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumabL Zabaglo, O Stoss, J Rüschoff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1994
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials GroupJ Verweij, J Wanders, A L Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Successful re-treatment with taxol after major hypersensitivity reactionsD M Peereboom, R C Donehower, E A Eisenhauer, et al.
Breast (Edinburgh, Scotland)|January 26, 2013
Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodesM Saghatchian, S Mook, G Pruneri, et al.
Critical Reviews in Oncology/Hematology|March 4, 2008
A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristicsV Durbecq, L Ameye, I Veys, et al.
Pageof 19